Long-Term Tolerability and Safety of Lamotrigine Extended-Release: Pooled Analysis of Three Clinical Trials

被引：0
|
作者：
Victor Biton
Bassel F. Shneker
Dean Naritoku
Anne E. Hammer
Alain Vuong
Paul T. Caldwell
John A. Messenheimer
机构：
[1] Arkansas Epilepsy Program,Department of Neurology
[2] Ohio State University,Departments of Neurology and Pharmacology
[3] University of South Alabama,undefined
[4] GlaxoSmithKline,undefined
来源：
Clinical Drug Investigation | 2013年 / 33卷
关键词：
Lamotrigine; Partial Seizure; Toxic Epidermal Necrolysis; Clinical Laboratory Test; Johnson Syndrome;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：359 / 364
页数：5
相关论文
共 50 条
  • [11] Efficacy and tolerability of fluvastatin extended-release delivery system:: A pooled analysis
    Ballantyne, CM
    Pazzucconi, F
    Pintó, X
    Reckless, JP
    Stein, E
    McKenney, J
    Bortolini, M
    Chiang, YT
    CLINICAL THERAPEUTICS, 2001, 23 (02) : 177 - 192
  • [12] Secukinumab pooled and long-term safety: analysis of 19 psoriasis clinical trials
    van de Kerkhof, P.
    Reich, K.
    Leonardi, C.
    Blauvelt, A.
    Mehta, N.
    Tsai, T-F
    You, R.
    Papanastasiou, P.
    Milutinovic, M.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 (05) : E259 - E260
  • [13] Long-term safety and tolerability of erenumab in episodic migraine: A pooled analysis from two clinical trials and their extension phases
    Ashina, M.
    Reuter, U.
    Dodick, D. W.
    Zhang, F.
    Ritter, S.
    Stites, T.
    Lima, G. Paiva da Silva
    Arkuszewski, M.
    Goadsby, P. J.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 268 - 269
  • [14] Long-term safety and tolerability of erenumab in episodic migraine: A pooled analysis from two clinical trials and their extension phases
    Ashina, M.
    Reuter, U.
    Dodick, D. W.
    Zhang, F.
    Ritter, S.
    Stites, T.
    Lima, G. Paiva Da Silva
    Arkuszewski, M.
    Goadsby, P. J.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
  • [15] Safety and tolerability of extended-release niacin-laropiprant: Pooled analyses for 11,310 patients in 12 controlled clinical trials
    McKenney, James
    Bays, Harold
    Gleim, Gilbert
    Mitchel, Yale
    Kuznetsova, Olga
    Sapre, Aditi
    Sirah, Waheeda
    Maccubbin, Darbie
    JOURNAL OF CLINICAL LIPIDOLOGY, 2015, 9 (03) : 313 - 325
  • [16] Long-Term Safety and Tolerability of Once-Daily Mesalamine Extended-Release Capsules in Patients With Ulcerative Colitis
    Lichtenstein, Gary R.
    Barrett, Andrew C.
    Bortey, Enoch
    Paterson, Craig
    Forbes, William P.
    GASTROENTEROLOGY, 2013, 144 (05) : S432 - S432
  • [17] Long-term safety and tolerability of Apremilast in patients with psoriasis: pooled safety analysis of the ESTEEM 1 and 2 trials
    Foley, P.
    Reich, K.
    Papp, K.
    Gordon, K. B.
    Griffiths, C. E. M.
    Chimenti, S.
    Lopez-Estebaranz, J. L.
    Gottlieb, A. B.
    Shah, Kamal
    Hu, ChiaChi
    Day, Robert M.
    Paul, Carle
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 37 - 37
  • [18] Efficacy and safety of an extended-release niacin (Niaspan): A long-term study
    Capuzzi, DM
    Guyton, JR
    Morgan, JM
    Goldberg, AC
    Kreisberg, RA
    Brusco, OA
    Brody, J
    AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (12A): : 74U - 81U
  • [19] Safety and tolerability of ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules in older patients: a pooled analysis of two clinical trials
    Wilson, Jacquelyn G.
    Bass, Almasa
    Pixton, Glenn C.
    Wolfram, Gernot
    Rauck, Richard L.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (01) : 91 - 99
  • [20] Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
    Mease, Philip J.
    Gladman, Dafna D.
    Gomez-Reino, Juan J.
    Hall, Stephen
    Kavanaugh, Arthur
    Lespessailles, Eric
    Schett, Georg
    Paris, Maria
    Delev, Nikolay
    Teng, Lichen
    Wollenhaupt, Juergen
    ACR OPEN RHEUMATOLOGY, 2020, 2 (08) : 459 - 470
12345